To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers

NCT03867331 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Malaria,Falciparum

Interventions

BIOLOGICAL: 5 microgram VLPM01
BIOLOGICAL: 15 microgram VLPM01
BIOLOGICAL: 30 microgram VLPM01
OTHER: Plasmodium falciparum challenge

Sponsor

VLP Therapeutics